psyence

Psyence BioMed Announces Approval for Use of PsyLabs Psilocybin Product in Phase IIb Clinical Trial

NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical…

3 weeks ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

June 18, 2025 17:36 ET  | Source: Psyence Group Inc. TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc.…

7 months ago